Orchard Therapeutics

Orchard Therapeutics, a British company developing gene therapy for rare genetic diseases, has launched its Nasdaq IPO and is now reportedly worth $1.25B (€1B). This IPO propels Orchard to the handful of European biotechs worth €1B or more. The new money might help with the marketing and manufacture of Strimvelis, an EMA-approved gene therapy for […]

Orchard Therapeutics raised $150M (€132M) in Series C financing to bring its gene therapies from clinical testing to regulatory approval. The British biotech will use the funding to develop its most advanced clinical programs, which aim to treat rare inherited metabolic and immune system diseases. The news follows Orchard’s acquisition of GSK’s entire gene therapy […]

Orchard Therapeutics has received a fourth Rare Pediatric Disease Designation from the FDA for its gene therapy candidate for metachromatic leukodystrophy. Orchard Therapeutics, based in London, has received a Rare Pediatric Disease Designation form the FDA for its gene therapy OTL-200. The treatment is for patients with metachromatic leukodystrophy (MLD), a fatal genetic disease that causes […]